"Biotechnology firm MannKind (MNKD) based out of California is focused predominately on creating products to help alleviate diabetes and cancer patients. The company's stock has been basically flat the past 52-weeks sitting right between its 52-week high and low. Chairman, CEO, and major shareholder Alfred Mann seems to think there is a great value though buying an astounding 40 million shares on December 21 at $2.59 equating to a $103.6 million worth of stock. As is the case with most biotechnology stocks, the balance sheet is not pretty and MannKind is no exception as the company was just about to run out of cash until it recently authorized the sale and dilutive effect of issuing another 200 million shares while still sitting on over $400 million in debt. On the flip side though, the company has a promising and if approved, very lucrative diabetes treatment drug and the Chairman/CEO seems to think there is great promise through this large insider purchase. I'd see this is as potentially a nice speculative buy."

http://seekingalpha.com/article/1091591-insider-alert-are-these-the-stocks-to-buy-in-2013?source=yahoo